Evidence map›Paper›PMID 36033245›Full record

ArticleJournal of the Intensive Care Society2022

Cellular and molecular mechanisms of IMMunE dysfunction and Recovery from SEpsis-related critical illness in adults: An observational cohort study (IMMERSE) protocol paper.

Matthew Fish, Kate Arkless, Aislinn Jennings, Julie Wilson, Michael J Carter, Gill Arbane, Sara Campos, Neus Novellas, Rianne Wester, Nedyalko Petrov and 10 more

Abstract read
In one paragraph

Article in Journal of the Intensive Care Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Matthew FishSchool of Immunology and Microbial Sciences, Kings College London, London, UK.
Kate ArklessInstitute of Pharmaceutical Science, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
Aislinn JenningsSchool of Immunology and Microbial Sciences, Kings College London, London, UK.
Julie WilsonSchool of Immunology and Microbial Sciences, Kings College London, London, UK.
Michael J CarterDepartment of Women and Children's Health, King's College London, London, UK.
Gill ArbaneDepartment of Intensive Care Medicine, Guy's and St Thomas' NHS Foundation Trust, St Thomas' Hospital, London, UK.
Sara CamposDepartment of Intensive Care Medicine, Guy's and St Thomas' NHS Foundation Trust, St Thomas' Hospital, London, UK.ORCID https://orcid.org/0000-0001-7753-0307
Neus NovellasDepartment of Intensive Care Medicine, Guy's and St Thomas' NHS Foundation Trust, St Thomas' Hospital, London, UK.
Rianne WesterNIHR Guy's and St Thomas' Biomedical Research Centre at Guy's and St Thomas NHS Foundation Trust, St Thomas' Hospital, London, UK.
Nedyalko PetrovNIHR Guy's and St Thomas' Biomedical Research Centre at Guy's and St Thomas NHS Foundation Trust, St Thomas' Hospital, London, UK.
Umar NiaziFaculty of Life Sciences, King's College London, London, UK.ORCID https://orcid.org/0000-0001-7176-8883
Barney SandersonDepartment of Intensive Care Medicine, Guy's and St Thomas' NHS Foundation Trust, St Thomas' Hospital, London, UK.ORCID https://orcid.org/0000-0002-9621-143X
Richard EllisNIHR Guy's and St Thomas' Biomedical Research Centre at Guy's and St Thomas NHS Foundation Trust, St Thomas' Hospital, London, UK.
Mansoor SaqiFaculty of Life Sciences, King's College London, London, UK.
Jo SpencerSchool of Immunology and Microbial Sciences, Kings College London, London, UK.
Mervyn SingerBloomsbury Institute of Intensive Care Medicine, UCL, London, UK.ORCID https://orcid.org/0000-0002-1042-6350
Rocio T Martinez-NunezSchool of Immunology and Microbial Sciences, Kings College London, London, UK.
Simon PitchfordInstitute of Pharmaceutical Science, School of Cancer and Pharmaceutical Sciences, King's College London, London, UK.
Chad M SwansonSchool of Immunology and Microbial Sciences, Kings College London, London, UK.ORCID https://orcid.org/0000-0002-6650-3634
Manu Shankar-HariSchool of Immunology and Microbial Sciences, Kings College London, London, UK.ORCID https://orcid.org/0000-0002-5338-2538

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sepsis is a common illness. Immune responses are considered major drivers of sepsis illness and outcomes. However, there are no proven immunomodulator therapies in sepsis. We hypothesised that in-depth characterisation of sepsis-specific immune trajectory may inform immunomodulation in sepsis-related critical illness. We describe the protocol of the IMMERSE study to address this hypothesis. We include critically ill sepsis patients without documented immune comorbidity and age-sex matched cardiac surgical patients as controls. We plan to perform an in-depth biological characterisation of innate and adaptive immune systems, platelet function, humoral components and transcriptional determinants of the immune system responses in sepsis. This will be done at pre-specified time points during their critical illness to generate an illness trajectory. The sample size for each biological assessment is different and is described in detail. In summary, the overall aim of the IMMERSE study is to increase the granularity of longitudinal immunology model of sepsis to inform future immunomodulation trials.

Indexed as

immunologylymphocyteSepsistranscriptomics

Identifiers

PMID36033245
PMCPMC9411781

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.